CFTR and cystic fibrosis: MRT5005, which encodes the CFTR protein as an inhaled mRNA drug, had undergone a randomized, double-blind, placebo-controlled phase 1/2 clinical study (NCT03375047) and received Fast Track designation for treatment of CF by the FDA [3].